Rigel Pharmaceuticals (RIGL) Change in Acquisitions & Divestments (2010 - 2026)

Rigel Pharmaceuticals' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $15.9 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 43.65% year-over-year to $15.9 million in Q1 2026; TTM through Mar 2026 was $66.0 million, a 55.05% increase from a year earlier, with the FY2025 full-year figure at $61.1 million, up 53.98% from the prior year.
• Change in Acquisitions & Divestments climbed to $15.9 million in Q1 2026 per RIGL's latest filing, from $13.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $29.8 million in Q1 2022 and bottomed at $6.0 million in Q4 2023.
• The 5-year median for Change in Acquisitions & Divestments is $15.6 million (2023), against an average of $15.3 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 2002.72% in 2022 and slumped 71.95% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $21.2 million in 2022, then sank by 71.65% to $6.0 million in 2023, then rose by 12.5% to $6.8 million in 2024, then soared by 100.73% to $13.5 million in 2025, then advanced by 17.68% to $15.9 million in 2026.
• Per Business Quant, the three latest RIGL Change in Acquisitions & Divestments figures stand at $15.9 million (Q1 2026), $13.5 million (Q4 2025), and $20.7 million (Q3 2025).